Genmab A/S Files 6-K: Major Shareholder Announcement
Ticker: GNMSF · Form: 6-K · Filed: Sep 23, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Sep 23, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-announcement, sec-filing, regulatory-update
Related Tickers: GMAB
TL;DR
Genmab filed a 6-K for a major shareholder update on Sept 23. Check ownership changes.
AI Summary
Genmab A/S filed a Form 6-K on September 23, 2025, reporting a major shareholder announcement dated September 23, 2025. This filing is incorporated by reference into several of Genmab's S-8 registration statements.
Why It Matters
This filing provides crucial updates on significant ownership changes, which can impact stock price and investor confidence.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of shareholder information and does not indicate any immediate financial distress or significant operational changes.
Key Players & Entities
- Genmab A/S (company) — Registrant
- September 23, 2025 (date) — Filing and Announcement Date
- 001-38976 (other) — SEC File Number
- 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876 (other) — S-8 Registration Statement File Numbers
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report a Company Announcement dated September 23, 2025, specifically a Major Shareholder Announcement.
When was this Form 6-K filed?
This Form 6-K was filed on September 23, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Which SEC registration statements does this filing get incorporated into?
This filing is incorporated by reference into Genmab A/S's registration statements on Form S-8 with file numbers 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876.
What exhibit is included with this filing?
Exhibit 99.1 is the Company Announcement dated September 23, 2025, regarding a Major Shareholder Announcement, and Exhibit 99.2 is a standard form for notification.
Filing Stats: 227 words · 1 min read · ~1 pages · Grade level 14.1 · Accepted 2025-09-23 10:56:00
Filing Documents
- gmab_20250923xx6k.htm (6-K) — 14KB
- gmab_20250923xxex99d1.htm (EX-99.1) — 15KB
- genmab_logoa.jpg (GRAPHIC) — 56KB
- gmab_20250923xxex99d2.htm (EX-99.2) — 16KB
- gmab_20250923xxex99d2001.jpg (GRAPHIC) — 126KB
- gmab_20250923xxex99d2002.jpg (GRAPHIC) — 101KB
- gmab_20250923xxex99d2003.jpg (GRAPHIC) — 118KB
- gmab_20250923xxex99d2004.jpg (GRAPHIC) — 93KB
- gmab_20250923xxex99d2005.jpg (GRAPHIC) — 91KB
- gmab_20250923xxex99d2006.jpg (GRAPHIC) — 111KB
- gmab_20250923xxex99d2007.jpg (GRAPHIC) — 98KB
- gmab_20250923xxex99d2008.jpg (GRAPHIC) — 218KB
- gmab_20250923xxex99d2009.jpg (GRAPHIC) — 129KB
- 0001434265-25-000078.txt ( ) — 1615KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2025 COMMISSION FILE NUMBER 001-38976 Genmab AS (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab AS's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Company Announcement Dated September 2 3 , 2025 Major Shareholder Announcement 99.2 Standard form for notification of major holdings SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GENMAB AS BY s Anthony Pagano Name Anthony Pagano Title Executive Vice President Chief Financial Officer DATE SEPTEMBER 23, 2025